Allergic contact dermatitis from topical doxepin: Food and Drug Administration's postmarketing surveillance experience - 29/08/11
Doi : 10.1067/mjd.2003.46
Abstract |
A total of 26 postmarketing cases of allergic contact dermatitis to doxepin 5% cream were reported to the Food and Drug Administration. Our findings suggest that allergic contact dermatitis was more common when treatment duration exceeded the recommended 8 days. Allergic contact dermatitis to doxepin cream should be considered in patients whose condition fails to improve or worsens with doxepin use. (J Am Acad Dermatol 2003;48:294-6.)
Le texte complet de cet article est disponible en PDF.Plan
 | Funding sources: None. |
| Conflict of interest: None identified. |
 | The views expressed are those of the author and do not necessarily represent those of, nor imply endorsement from, the Food and Drug Administration or the US Government. |
| Reprint requests: Renan A. Bonnel, PharmD, MPH, 5600 Fishers Ln, Room 15B-23, HFD-430, Rockville, MD 20857. |
© 2003
American Academy of Dermatology, Inc. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 48 - N° 2
P. 294-296 - février 2003 Retour au numéro
Article précédent
- Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-⍺ therapy
- Lotus Mallbris, Anders Ljungberg, Mari-Anne Hedblad, Per Larsson, Mona Ståhle-Bäckdahl
- Glucagonoma syndrome: Diagnosis and treatment
- Jianying Zeng, Baoxi Wang, Donglai Ma, Fang Li
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?